Sirolimus in Treating Patients With HIV-Related Kaposi's Sarcoma

Completed · Phase 1

Conditions studied: Sarcoma

In brief

RATIONALE: Drugs used in chemotherapy, such as sirolimus, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Sirolimus also may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This pilot study is studying sirolimus in treating patients with HIV-related Kaposi's sarcoma.

Key facts

Study ID

NCT00450320

Run by

AIDS Malignancy Consortium

People needed

7

Starts

2007-10-01

Expected to finish

2009-09-01

Last updated by the study team

2014-08-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Rebecca and John Moores UCSD Cancer Center — La Jolla, California, United States
• Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States
• Memorial Sloan-Kettering Cancer Center — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.